Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

280 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the efficacy and safety of ATG-F induction regimen using a single dose of ATG-F compared with a five-day dose regimen of ATG-F in anew kidney transplant recipients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients

NCT02392312

Kidney Transplant Recipients

COMPLETED

Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation

NCT04835948

Kidney Transplant; Complications Immunosuppression

COMPLETED

Comparison of ATG to Thymoglobuline in Renal Transplantation

NCT00861536

Transplantation, Kidney

COMPLETED PHASE4

Polyclonal Antilymphocyte Globulin (ATG) & Intestinal Immune Barrier After Kidney Transplantation

NCT02843841

UNKNOWN NA

Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor

NCT00733733

Renal Transplant Patients Recipients of a Kidney From a Non-Heart-Beating Donor

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To investigate the efficacy and safety of ATG-F induction regimen using a single dose of ATG-F compared with a five-day dose regimen of ATG-F in de novo kidney transplant recipients. The primary analysis of this study is to demonstrate the non-inferiority of the two regimens with regard to efficacy, defined as failure rate.

The secondary objective of the study is the assessment of safety and further efficacy parameters in terms of incidence of acute rejections, graft/patient survival, DGF(delayed graft function) and renal function

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

De Novo Kidney Transplant Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ATG-F single dosing group

Intravenous (IV)

Group Type EXPERIMENTAL

ATG-F

Intervention Type DRUG

Intravenous (IV)

ATG-F continuous dosing group

Intravenous (IV)

Group Type EXPERIMENTAL

ATG-F

Intervention Type DRUG

Intravenous (IV)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ATG-F

Intravenous (IV)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with end stage kidney disease who is a suitable candidate for primary kidney transplantation.
* Patients scheduled to undergo renal allograft transplantation with compatible ABO blood type.
* Peak PRA \<50%
* Females of childbearing potential must have a negative pregnancy test within 48hrs prior to randomization and reliable methods of contraception should be started 4 weeks prior to and during the whole study.
* Patients capable to understand the purposes and risks of the study, who are willing and able to participate in the study and from whom written and dated informed consent to participate in the study is obtained.

Exclusion Criteria

* Subject has previously received or is receiving an organ transplant other than kidney
* Subject is receiving double-kidney transplant.
* Subject is receiving an ABO incompatible or T-cells cross match positive transplant.
* Cold ischemia time of allograft is \> 24 hours before kidney transplantation surgery.
* Subject is receiving organ from a Human Leukocyte Antibody (HLA) identical donor.
* Known contraindication to administration of ATG-F, including:

* Subject has known hypersensitivity to rabbit proteins
* Subject with severe thrombocytopenia
* Subject with bacterial, viral or mycotic infections which are not under therapeutically control
* Subject has known hypersensitivity to tacrolimus, macrolide antibiotics, mycophenolate mofetil, or any of the product excipients.
* Subject is unlikely to comply with the visits scheduled in the protocol in the opinion of the investigator or has a history of non-compliance.
* Pregnant women, nursing mothers, lactating women, and women of child-bearing potential who are unwilling to use reliable contraception during the study and for 6 weeks following completion of the study.
* Patients with evidence of active liver disease (liver function tests ≥ 2 times upper limit of normal) or the presence of a chronic active hepatitis B or C.
* Recipient or donor is seropositive for human immunodeficiency virus (HIV).

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No